title: [Acute nongonococcal epididymitis--pharmacological and therapeutic aspects of levofloxacin].
abstract: We performed basic and clinical studies on the effects of a new oral quinolone derivative, levofloxacin (LVFX, Code No. DR 3355) which is an optical l-isomer of ofloxacin, in acute epididymitis. LVFX was administered in a dose of 200 mg to prostatic cancer patients 2 hours before operation. The mean concentration of LVFX in the tissues of testis and epididymis were 4.73 micrograms/g and 313-3.6 micrograms/g, respectively. Tissue/Serum ratios were 1.63 and 1.16-1.32, respectively. LVFX was administered in a dose of 100 mg three times daily for 13 days to healthy male volunteers. Semen and blood samples were taken 2 hrs after 7th and last day of administration. The concentration of LVFX in semen were 1.19 micrograms/ml (7th day) and 1.32 micrograms/ml (13th day). Semen/serum ratios were 1.12 and 1.26, respectively. No affection of LVFX on the sperm was observed. Antimicrobial activity of LVFX to C. trachomatis showed good MICs of 0.25-1.0 micrograms/ml. LVFX was administered in a dose of 100 mg two or three times daily for 14 days to 23 patients with acute epididymitis. The overall efficacy rate based on a criteria for acute epididymitis showed 100% (excellent: 16, good: 4, 20/20). A better efficacy rate was obtained on the 14th day than 7th day. No subjective or objective adverse reactions were observed.
authors.affiliation: Department of Urology, Tokyo Kyosai Hospital.
authors.forename: I
authors.initials: I
authors.lastname: Saito
authors.forename: A
authors.initials: A
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Saiko
authors.forename: M
authors.initials: M
authors.lastname: Yokozawa
authors.forename: K
authors.initials: K
authors.lastname: Ono
authors.forename: K
authors.initials: K
authors.lastname: Miyata
authors.forename: R
authors.initials: R
authors.lastname: Miyamura
authors.forename: O
authors.initials: O
authors.lastname: Hamaya
authors.forename: K
authors.initials: K
authors.lastname: Kaneko
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D002692:Chlamydia trachomatis / Q000187:drug effects; D004822:Epididymis / Q000378:metabolism; D004823:Epididymitis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013076:Sperm Count / Q000187:drug effects; D013081:Sperm Motility / Q000187:drug effects; D013094:Spermatozoa / Q000187:drug effects
chemical_list: D064704:Levofloxacin; D015242:Ofloxacin